1. Field of the Invention
The present invention relates generally to devices for applying localized liquid therapy and/or thermotherapy to an afflicted area of the patient. More particularly, this invention relates to a device, and method of use thereof, which directly applies a liquid, most usually a water based liquid to a selected area to create the desired therapeutic effect, most usually a localized hyperthermia, which is effective in treating localized afflictions, such as moles, lesions, tumors, malignancies, both surface and subcutaneous, and the like, or a therapeutic lavage or irrigation.
2. Description of Related Art
Heat and cold have both been used to effectively treat afflicted patients. Directly applying liquid to afflicted cells is also well known. Cold has often been used as a localized treatment, while heat has been, and is currently used as both a localized and total body treatment. Using heat to treat a localized afflicted area of an afflicted patient is most relevant to the present invention.
The search continues to ways to effectively treat wounds, tumors and similar disorders while minimizing adverse collateral effects. For example, assignee has been a leader in treating open wounds through a process known as Vacuum Assisted Closure™ (“V.A.C.®”). In a similar vein, localized thermotherapy, primarily localized hyperthermia, has also shown promise as a treatment modality which is capable of producing beneficial therapeutic effects without significant adverse collateral effects for certain conditions. However, the localized hyperthermic treatment modalities in the prior art, all suffer from serious drawbacks, limitations, or side effects.
Research has demonstrated that heating cancerous, or other abnormal cells to over about 42° Celsius (“C”) can kill the abnormal cells, while causing little damage to the surrounding normal cells. This treatment is temperature sensitive. Heating the cancel cells, for example, to a temperature between nominal body temperatures, 37° C. and approximately 41° C. or greater can seriously damage them. To maximize patient safety, this hyperthermia treatment must be localized.
The variety of available heat transfer methods for localized thermotherapy is limited. Heat is transferred in three ways, radiation, convection, or conduction. The heat transfer medium creating the localized hyperthermia can be either heated in situ or be heated exogenously, before being placed upon the patient. The medium can either be placed in direct contact with the afflicted cells or, transfer heat to the afflicted cells through an intermediary.
Localized hyperthermia therapy is presently used in treating prostate afflictions, breast cancer, and other afflictions. This modality involves placing implants about the afflicted patient's afflicted cells, and then heating the implants by radiating EMF or ultrasonic energy thereto. The heat from the implants then migrates into the afflicted tissue, via conduction, thereby raising the temperature of the afflicted cells. Several issued patents demonstrate variations of this technique. Issues relating to possible adverse affects of exposure to both radiation, and radiated energy abound. However, as most suffers of prostate cancer are older men who are past the age of fathering children, and female breasts are relatively remote from the female reproductive organs, the possible long-term adverse collateral effects of using such radiant energy treatments are minimized.
Applicant has discovered various patents that employ and exemplify other energy transfer methods and media in creating localized hyperthermias. These patents include Guibert, U.S. Pat. No. 4,595,008, issued Jun. 17, 1986, and Shantha, U.S. Pat. No. 5,195,965 issued Mar. 23, 1993.
Various other heated liquid devices and methods of treating hollow organs or body orifices exist, and operate in the same basic manner. However, there is a need for a system and method for the creation of a localized therapeutic hyperthermia by means of a heated liquid directly contacting afflicted cells for a period of significant duration. More particularly, there is a need for a device, or method of treatment, which involves, selecting a therapeutic liquid, heating the selected liquid through conduction so as to avoid EMF or ultrasonic radiation, placing a therapeutic applicator about the afflicted cells, and circulating the heated fluid through the therapeutic applicator, thereby creating a localized hyperthermia in the afflicted cells within the circumference of the applicator. Furthermore it would be beneficial to provide the use of a localized hyperthermic modality in conjunction with Vacuum Assisted Closure™, (“V.A.C.®”) of open wounds. It is towards the fulfillment of these needs that the present invention is directed.
The present invention is a novel device used to create a localized therapeutic effect on afflicted cells on an afflicted patient. These effects include cleaning, disinfecting, cooling, heating, and methods of use thereof. The device embodying the present invention comprises a therapeutic liquid, liquid supply means, liquid energizing means, circulating means, and control means. The device may also be used in conjunction with V.A.C.® therapy. These elements interface, and are employed, as briefly described below.
An appropriate therapeutic liquid is selected. Most often this liquid will be water, or a liquid comprising at least 90% water on a weight/weight (“w/w %”) basis. Thermal energy is directly applied to, or taken from, the liquid. Most commonly the liquid will be heated. This energy transfer is regulated by the control means, which compares the actual liquid temperature with a selected reference temperature. The heated or cooled liquid is then used to create a local therapeutic effect. Control means also comprises system control means that monitors and regulates the overall operation of the device.
The balance of this description presumes that the liquid is heated rather than cooled. The liquid will either be recirculated if a closed loop embodiment is selected, or be used once and discarded if an open loop embodiment is selected. An afflicted area, such as a mole, skin cancer, or the like, is located on the afflicted patient. The afflicted area may be on the skin, or subcutaneous.
The circulation means comprises supply means, recovery means, and applicator means. The applicator has an open bottom or bottom portion and is placed about the afflicted cells on the skin of the patient, and most likely, some of the surrounding non-afflicted cells on the patient's skin as well. Before commencing the application of the therapeutic liquid, a fluid tight seal must be established between the patient and the application means; this seal must be maintained for at least the duration of the liquid application. The applicator may also comprise a fluid tight V.A.C.® dressing. The liquid flows from the liquid supply means, into the supply conduit of the circulation means, into the applicator means, and then into the return conduit. The liquid is then either recirculated, or discarded.
Circulation means also likely comprises liquid pressurization means that likely comprise a pump; though a sealed pressurized embodiment is also contemplated. Alternatively, gravity flow, or the negative pressure associated with V.A.C.®, roughly 150 mm Hg, in an open loop system could be considered. In a preferred embodiment, the pump is placed on the return side of the circulation means. This configuration has the advantage of applying negative pressure to the application means thereby creating a self actuated negative pressure seal between the application means and the patient's skin for the duration of therapeutic liquid application. Alternatively, a sealing mechanism could be used to maintain the necessary seal between the application means the afflicted patient. Applying pressure to the liquid also creates a more rapid circulation of the liquid to the epidermal region, which could have beneficial therapeutic effects.
Accordingly, an object of the present invention is to provide a device that employs an exogenously heated fluid to provide direct thermotherapy to an afflicted portion of a patient.
Another object of the present invention is to provide localized thermal therapy where the perimeter of the afflicted portion of the patient is within the boundaries of the therapy applicator of the present invention.
A further object of the present invention is to provide a novel device that provides lavage to an afflicted patient.
Yet another object of the present invention is to combine the therapeutic effects of the present invention with the positive effects associated with V.A.C.®.
The foregoing has outlined some of the more pertinent objects of the present invention. These objects should be construed to be merely illustrative of some of the more prominent features and applications of the invention. Many other beneficial results can be attained by applying the disclosed invention in a different manner or by modifying the invention as will be described. Accordingly, other objects and a fuller understanding of the invention may be had by referring to the following Detailed Description of the Invention, which includes the preferred embodiment.
These and other features and advantages of the invention will now be described with reference to the drawings of certain preferred embodiment, which are intended to illustrate and not to limit the invention, and wherein like reference numbers refer to like components, and in which:
Although those of ordinary skill in the art will readily recognize many alternative embodiments, especially in light of the illustrations provided herein, this detailed description is exemplary of the preferred embodiment of the present invention as well as alternate embodiments, the scope of which is limited only by the claims that may be drawn hereto.
The details of the preferred embodiments of the present invention are graphically and schematically illustrated in the accompanying drawings. Like elements in the drawings are represented by like numbers, and any similar elements are represented by the like numbers with a different lower case letter suffix.
The preferred embodiments of the present invention, referred to throughout by the general reference 10, are intended to treat an afflicted patient 11, and particularly an afflicted area of the patient's skin 12, or the area immediately subcutaneous thereto, which is surrounded by a healthy area 13 of patient 11. As shown in
Embodiment 10 may be used with a variety of liquids, in addition to water, and may provide either localized heating or localized cooling, in addition to direct contact effects from the liquid such as disinfection, irrigation, lavage, and so forth. However, to promote ease of understanding, the further description shall focus on the hyperthermia delivering embodiment using a liquid which on a w/w % basis is at least 90% water.
As shown in
Control means 21 is connected to both liquid heating means 19 and liquid temperature means 20 and coacts therewith in a manner more fully described below. Measuring means 20 may be located as necessary, depending upon both the speed of liquid flow, and the degree of temperature loss encountered. In a low speed flow embodiment, such as in
The precision heated liquid is delivered to the afflicted area 12 of patient 11 via liquid supply means 15, therapy site liquid applicator 18, liquid return means 16, and liquid movements means 17 all of which coact as described more fully below. Liquid movement means 17 generally comprises a pump of adequate capacity, as is well known in the art. Although the exact connection configuration of means 17 depends upon the overall system configuration of embodiment 10, in the presently preferred embodiment of embodiment 10, shown in
Some applications may require avoiding applying negative pressure to the afflicted area 12, by applying positive pressure as shown in
As shown in
Returning now to the specific embodiment shown in
Supply end 27 of liquid supply means 15 is placed in liquid tight operative engagement with outlet 22 of reservoir 14. Delivery end 29 of liquid supply means 15 is placed in fluid tight engagement with applicator 18 via liquid supply means receptor 34 thereof. Applicator 18 is arranged about afflicted area 12 so that the inner surface 33 of open bottom 31 surrounds area 12, and most likely area 13, in fluid tight engagement. Cavity 38 is defined by inner surface 33, afflicted area 12, and the portion of area 13 surrounded by open bottom 31, as described above.
In this configuration pump 17 is placed between end 36 of liquid return line 16 and end 37 of liquid return line 16 in the following manner. End 26 of liquid return line 16 is placed in fluid tight engagement with liquid return means receptor 35. Pump intake end 36 of liquid return line 16 is placed in fluid tight engagement with pump intake 24. Any desired filtration means (not shown) could also logically be placed in proximity thereto. Pump output end 37 of liquid return means 16 is placed in fluid tight engagement with outlet 25 of pump 17. Reservoir inlet end 28 of liquid return means 16 is placed in fluid tight engagement with inlet 23 of reservoir 14.
The system control means regulators the overall operation of the embodiment 10, in a manner well known to those skilled in the art. Actuation means, timing means, data collection means, data recordation means, alarm means, and emergency shutoff means (all not shown) are just a few of the possible functions which could comprise the functions carried out by system control means. Existing data processing means remote from the location of the embodiment 10 could well perform some of these functions.
The embodiment 10 would be used in the following manner. The embodiment is connected to a power source (not shown) in reasonable proximity to the afflicted patient 11, convenient for attachment about afflicted area 12. If necessary, the control means are activated. A selected temperature is entered into set point controller 21. If desired, a selected duration is entered into the optional timing means. Any temperature or other alarm values are also entered into the system control means. Applicator 18 is placed about afflicted area 12. Embodiment 10 is activated. When the temperature of the liquid in reservoir 14 approximates the selected temperature set into controller 21, pump 17 is enabled. Upon actuation, pump 17 first partially evacuates cavity 38, thereby creating a negative pressure differential. This negative pressure acts to hold applicator 18 in place about afflicted area 12. Heated liquid then exits reservoir 14 through outlet end 27 of liquid supply means 15, and passes through supply conduit liquid supply means 15, enters applicator 18, comes into contact with afflicted area 12, transfers heat to afflicted area 12, and exits applicator 18 into liquid return means 16. This liquid passes through the pump 17 and is returned into reservoir 14 through inlet end 28 of liquid return means 16, thereby completing the loop.
Certain advantages may accrue from moving the heated liquid rapidly through the embodiment. These advantages are believed to include better temperature control, a faster rate of heat transfer to the afflicted cells, a quicker attainment of thermal equilibrium, and a lower requirement for total system liquid. It is also anticipated that this device and modality would also be effective in treating cells subcutaneous the skin areas 12 and 13, placed within the open bottom 31 of the applicator 18.
Additional, an open loop system, as shown in
An additional embodiment would be to use a mild oxidizing agent as the fluid in this device. Such an agent, were it to have a greater affect upon afflicted cells, than non-afflicted cells, would provide an enhanced therapeutic effect in conjunction with the therapy herein described. An example of such a solution would be 3% Hydrogen peroxide, U.S.P. Likely a more benign disinfecting solution would be used, such as are well known to those skilled in the art, for irrigation or other treatment of wounds.
While the invention has been described herein with reference to certain preferred embodiments, these embodiments have been presented by way of example only, and not to limit the scope of the invention. Many other variations are possible, which would be obvious to one skilled in the art. Accordingly, the scope of the invention should be identified only in accordance with the claims that follow.
This application is a continuation of U.S. application Ser. No. 10/320,211 filed Dec. 16, 2002 now U.S. Pat. No. 7,422,576, which is a continuation of U.S. application Ser. No. 09/590,333, filed Jun. 8, 2000, now U.S. Pat. No. 6,520,982. Priority is claimed to all of the above-mentioned applications, and each application is hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
1355846 | Rannells | Oct 1920 | A |
2272481 | Rinkes | Feb 1942 | A |
2547758 | Keeling | Apr 1951 | A |
2632443 | Lesher | Mar 1953 | A |
2682873 | Evans et al. | Jul 1954 | A |
2910763 | Lauterbach | Nov 1959 | A |
2969057 | Simmons | Jan 1961 | A |
3066672 | Crosby, Jr. et al. | Dec 1962 | A |
3367332 | Groves | Feb 1968 | A |
3520300 | Flower, Jr. | Jul 1970 | A |
3568675 | Harvey | Mar 1971 | A |
3648692 | Wheeler | Mar 1972 | A |
3682180 | McFarlane | Aug 1972 | A |
3826254 | Mellor | Jul 1974 | A |
4080970 | Miller | Mar 1978 | A |
4090507 | Van Horn | May 1978 | A |
4096853 | Weigand | Jun 1978 | A |
4112947 | Nehring | Sep 1978 | A |
4139004 | Gonzalez, Jr. | Feb 1979 | A |
4165748 | Johnson | Aug 1979 | A |
4184510 | Murry et al. | Jan 1980 | A |
4192297 | Labrecque | Mar 1980 | A |
4233969 | Lock et al. | Nov 1980 | A |
4245630 | Lloyd et al. | Jan 1981 | A |
4256109 | Nichols | Mar 1981 | A |
4261363 | Russo | Apr 1981 | A |
4275721 | Olson | Jun 1981 | A |
4284079 | Adair | Aug 1981 | A |
4297995 | Golub | Nov 1981 | A |
4333468 | Geist | Jun 1982 | A |
4353359 | Milbauer | Oct 1982 | A |
4373519 | Errede et al. | Feb 1983 | A |
4382441 | Svedman | May 1983 | A |
4392853 | Muto | Jul 1983 | A |
4392858 | George et al. | Jul 1983 | A |
4419097 | Rowland | Dec 1983 | A |
4465485 | Kashmer et al. | Aug 1984 | A |
4475909 | Eisenberg | Oct 1984 | A |
4480638 | Schmid | Nov 1984 | A |
4525166 | Leclerc | Jun 1985 | A |
4525374 | Vaillancourt | Jun 1985 | A |
4540412 | Van Overloop | Sep 1985 | A |
4543100 | Brodsky | Sep 1985 | A |
4548202 | Duncan | Oct 1985 | A |
4551139 | Plaas et al. | Nov 1985 | A |
4569348 | Hasslinger | Feb 1986 | A |
4595008 | Guibert | Jun 1986 | A |
4605399 | Weston et al. | Aug 1986 | A |
4608041 | Nielson | Aug 1986 | A |
4640688 | Hauser | Feb 1987 | A |
4655754 | Richmond et al. | Apr 1987 | A |
4664662 | Webster | May 1987 | A |
4710165 | McNeil et al. | Dec 1987 | A |
4733659 | Edenbaum et al. | Mar 1988 | A |
4743232 | Kruger | May 1988 | A |
4758220 | Sundblom et al. | Jul 1988 | A |
4787888 | Fox | Nov 1988 | A |
4826494 | Richmond et al. | May 1989 | A |
4838883 | Matsuura | Jun 1989 | A |
4840187 | Brazier | Jun 1989 | A |
4863449 | Therriault et al. | Sep 1989 | A |
4872450 | Austad | Oct 1989 | A |
4878901 | Sachse | Nov 1989 | A |
4897081 | Poirier et al. | Jan 1990 | A |
4906233 | Moriuchi et al. | Mar 1990 | A |
4906240 | Reed et al. | Mar 1990 | A |
4919654 | Kalt et al. | Apr 1990 | A |
4941882 | Ward et al. | Jul 1990 | A |
4945901 | Burcke, Jr. | Aug 1990 | A |
4953565 | Tachibana et al. | Sep 1990 | A |
4969880 | Zamierowski | Nov 1990 | A |
4979938 | Stephen et al. | Dec 1990 | A |
4985019 | Michelson | Jan 1991 | A |
5037397 | Kalt et al. | Aug 1991 | A |
5086170 | Luheshi et al. | Feb 1992 | A |
5092858 | Benson et al. | Mar 1992 | A |
5100396 | Zamierowski | Mar 1992 | A |
5134994 | Say | Aug 1992 | A |
5149331 | Ferdman et al. | Sep 1992 | A |
5167613 | Karami et al. | Dec 1992 | A |
5176663 | Svedman et al. | Jan 1993 | A |
5195965 | Shantha | Mar 1993 | A |
5215522 | Page et al. | Jun 1993 | A |
5232453 | Plass et al. | Aug 1993 | A |
5241953 | Sykes | Sep 1993 | A |
5261893 | Zamierowski | Nov 1993 | A |
5278100 | Doan et al. | Jan 1994 | A |
5279550 | Habib et al. | Jan 1994 | A |
5298015 | Komatsuzaki et al. | Mar 1994 | A |
5342376 | Ruff | Aug 1994 | A |
5344415 | DeBusk et al. | Sep 1994 | A |
5358494 | Svedman | Oct 1994 | A |
5437622 | Carion | Aug 1995 | A |
5437651 | Todd et al. | Aug 1995 | A |
5458596 | Lax et al. | Oct 1995 | A |
5527293 | Zamierowski | Jun 1996 | A |
5549584 | Gross | Aug 1996 | A |
5556375 | Ewall | Sep 1996 | A |
5607388 | Ewall | Mar 1997 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5645081 | Argenta et al. | Jul 1997 | A |
5683438 | Grahn | Nov 1997 | A |
5735833 | Olson | Apr 1998 | A |
5871526 | Gibbs et al. | Feb 1999 | A |
6071267 | Zamierowski | Jun 2000 | A |
6135116 | Vogel et al. | Oct 2000 | A |
6200292 | French et al. | Mar 2001 | B1 |
6241747 | Ruff | Jun 2001 | B1 |
6287316 | Agarwal et al. | Sep 2001 | B1 |
6345623 | Heaton et al. | Feb 2002 | B1 |
6406447 | Thrash et al. | Jun 2002 | B1 |
6458109 | Henley et al. | Oct 2002 | B1 |
6488643 | Tumey et al. | Dec 2002 | B1 |
6493568 | Bell et al. | Dec 2002 | B1 |
6520982 | Boynton et al. | Feb 2003 | B1 |
6553998 | Heaton et al. | Apr 2003 | B2 |
6800074 | Henley et al. | Oct 2004 | B2 |
6814079 | Heaton et al. | Nov 2004 | B2 |
7144390 | Hannigan et al. | Dec 2006 | B1 |
7422576 | Boynton et al. | Sep 2008 | B2 |
20020077661 | Saadat | Jun 2002 | A1 |
20020115951 | Norstrem et al. | Aug 2002 | A1 |
20020120185 | Johnson | Aug 2002 | A1 |
20020143286 | Tumey | Oct 2002 | A1 |
Number | Date | Country |
---|---|---|
550575 | Aug 1982 | AU |
745271 | Apr 1999 | AU |
755496 | Feb 2002 | AU |
2005436 | Jun 1990 | CA |
26 40 413 | Mar 1978 | DE |
43 06 478 | Sep 1994 | DE |
295 04 378 | Oct 1995 | DE |
0100148 | Feb 1984 | EP |
0117632 | Sep 1984 | EP |
0161865 | Nov 1985 | EP |
0358302 | Mar 1990 | EP |
1018967 81 | Aug 2004 | EP |
692578 | Jun 1953 | GB |
2 195 255 | Apr 1988 | GB |
2 197 789 | Jun 1988 | GB |
2 220 357 | Jan 1990 | GB |
2 235 877 | Mar 1991 | GB |
2 333 965 | Aug 1999 | GB |
2 329 127 | Aug 2000 | GB |
4129536 | Apr 1992 | JP |
71559 | Apr 2002 | SG |
WO 8002182 | Oct 1980 | WO |
WO 8704626 | Aug 1987 | WO |
WO 9010424 | Sep 1990 | WO |
WO 9309727 | May 1993 | WO |
WO 9420041 | Sep 1994 | WO |
WO 9605873 | Feb 1996 | WO |
WO 9718007 | May 1997 | WO |
WO 9913793 | Mar 1999 | WO |
WO 0007653 | Feb 2000 | WO |
Entry |
---|
V.A. Solovev et al., Guidelines, The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”). |
V.A. Kuznetsov & N.a. Bagautdinov, “Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds,” in II All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov II”). |
V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) (“Solovev Abstract”). |
N.A. Bagautdinov, “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of the Soft Tissues,” Current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986);pp. 94-96 (certified translation). |
Louis C. Argenta, MD and Michael J. Morykwas, PhD; “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Clinical Experience”; Annals of Plastic Surgery, vol. 38, No. 6, Jun. 1997; pp. 563-576. |
Susan Mendez-Eastmen, RN; “When Wounds Won't Heal” RN Jan. 1998, vol. 61 (1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24. |
James H. Blackburn, II, MD, et al; “Negative-Pressure Dressings as a Bolster for Skin Grafts”; Annals of Plastic Surgery, vol. 40, No. 5, May 1998, pp. 453-457. |
John Masters; “Reliable, Inexpensive and Simple Suction Dressings”; Letter to the Editor, British Journal of Plastic Surgery, 1998, vol. 51 (3), p. 267; Elsevier Science/The British Association of Plastic Surgeons, UK. |
S.E. Greer, et al “The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of the Groin” British Journal of Plastic Surgery (2000), 53, pp. 484-487. |
George V. Letsou, MD., et al; “Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells Subjected to Cyclic Stretch”; Journal of Cardiovascular Surgery, 31, 1990, pp. 634-639. |
Orringer, Jay, et al; “Management of Wounds in Patients with Complex Enterocutaneous Fistulas”; Surgery, Gynecology & Obstetrics, Jul. 1987, vol. 165, pp. 79-80. |
International Search Report for PCT International Application PCT/GB95/01983; Nov. 23, 1995. |
PCT International Search Report for PCT International Application PCT/GB98/02713; Jan. 8, 1999. |
PCT Written Opinion; PCT International Application PCT/GB98/02713; Jun. 8, 1999. |
PCT International Examination and Search Report, PCT International Application PCT/GB96/02802; Jan. 15, 1998 & Apr. 29, 1997. |
PCT Written Opinion, PCT International Application PCT/GB96/02802; Sep. 3, 1997. |
Dattilo, Philip P., Jr., et al; “Medical Textiles: Application of an Absorbable Barbed Bi-directional Surgical Suture”; Journal of Textile and Apparel, Technology and Management, vol. 2, Issue 2, Spring 2002, pp. 1-5. |
Kostyuchenok, B.M., et al; “Vacuum Treatment in the Surgical Management of Purulent Wounds”; Vestnik Khirurgi, Sep. 1986, pp. 18-21 and 6 page English translation thereof. |
Davydov, Yu. A., et al; “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”; Vestnik Khirurgi, May 14, 1986, pp. 66-70, and 9 page English translation thereof. |
Yusupov. Yu. N., et al; “Active Wound Drainage”, Vestnik Khirurgi, vol. 138, Issue 4, 1987, and 7 page English translation thereof. |
Davydov, Yu. A., et al; “Bacteriological and Cytological Assessment of Vacuum Therapy for Purulent Wounds”; Vestnik Khirurgi, Oct. 1988, pp. 48-52, and 8 page English translation thereof. |
Davydov, Yu. A., et al; “Concepts for the Clinical-Biological Management of the Wound Process in the Treatment of Purulent Wounds by Means of Vacuum Therapy”; Vestnik Khirurgi, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof. |
Chariker, Mark E., M.D., et al; “Effective Management of incisional and cutaneous fistulae with closed suction wound drainage”; Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63. |
Egnell Minor, Instruction Book, First Edition, 300 7502, Feb. 1975, pp. 24. |
Egnell Minor: Addition to the Users Manual Concerning Overflow Protection—Concerns all Egnell Pumps, Feb. 3, 1983, pp. 2. |
Svedman, P.: “Irrigation Treatment of Leg Ulcers”, The Lancet, Sep. 3, 1983, pp. 532-534. |
Chinn, Steven D. et al.: “Closed Wound Suction Drainage”, The Journal of Foot Surgery, vol. 24, No. 1, 1985, pp. 76-81. |
Arnljots, Björn et al.: “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers”, Scand J. Plast Reconstr. Surg., No. 19, 1985, pp. 211-213. |
Svedman, P.: “A Dressing Allowing Continuous Treatment of a Biosurface”, IRCS Medical Science: Biomedical Technology, Clinical Medicine, Surgery and Transplantation, vol. 7, 1979, p. 221. |
Svedman, P. et al.: “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous or Intermittent Irrigation”, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133. |
K.F. Jeter, T.E. Tintle, and M. Chariker, “Managing Draining Wounds and Fistulae: New and Established Methods,” Chronic Wound Care, edited by D. Krasner (Health Management Publications, Inc., King of Prussia, PA 1990), pp. 240-246. |
G. {hacek over (Z)}ivadinović, V. ukić, {hacek over (Z)}. Maksimović, . Radak, and P. Pe{hacek over (s)}ka, “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Timok Medical Journal 11 (1986), pp. 161-164 (certified translation). |
F.E. Johnson, “An Improved Technique for Skin Graft Placement Using a Suction Drain,” Surgery, Gynecology, and Obstetrics 159 (1984), pp. 584-585. |
A.A. Safronov, Dissertation Abstract, Vacuum Therapy of Trophic Ulcers of the Lower Leg with Simultaneous Autoplasty of the Skin (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967) (certified translation). |
M. Schein, R. Saadia, J.R. Jamieson, and G.A.G. Decker, “The ‘Sandwich Technique’ in the Management of the Open Abdomen,” British Journal of Surgery 73 (1986), pp. 369-370. |
D.E. Tribble, An Improved Sump Drain-Irrigation Device of Simple Construction, Archives of Surgery 105 (1972) pp. 511-513. |
M.J. Morykwas, L.C. Argenta, E.I. Shelton-Brown, and W. McGuirt, “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation,” Annals of Plastic Surgery 38 (1997), pp. 553-562 (Morykwas I). |
C.E. Tennants, “The Use of Hypermia in the Postoperative Treatment of Lesions of the Extremities and Thorax,”Journal of the American Medical Association 64 (1915), pp. 1548-1549. |
Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in Surgery, Medicine, and the Specialties: A Manual of Its Practical Application, (W.B. Saunders Co., Philadelphia, PA 1909), pp. 17-25, 44-64, 90-96, 167-170, and 210-211. |
Non-Final Office Action date mailed Jan. 3, 2002 for U.S. Appl. No. 09/590,333. |
Response filed Jul. 2, 2002 to Non-Final Office Action date mailed Jan. 3, 2002 for U.S. Appl. No. 09/590,333. |
Notice of Allowance date mailed Oct. 9, 2002 for U.S. Appl. No. 09/590,333. |
Non-Final Office Action date mailed Aug. 20, 2004 for U.S. Appl. No. 10/320,211. |
Response filed Dec. 9, 2004 to Non-Final Office Action date mailed Aug. 20, 2004 for U.S. Appl. No. 10/320,211. |
Non-Final Office Action date mailed Feb. 17, 2005 for U.S. Appl. No. 10/320,211. |
Response filed Aug. 15, 2005 to Non-Final Office Action date mailed Feb. 17, 2005 for U.S. Appl. No. 10/320,211. |
Final Office Action date mailed Oct. 27, 2005 for U.S. Appl. No. 10/320,211. |
Response filed Mar. 27, 2006 to Final Office Action date mailed Oct. 27, 2005 for U.S. Appl. No. 10/320,211. |
Non-Final Office Action date mailed May 30, 2006 for U.S. Appl. No. 10/320,211. |
Response filed Nov. 30, 2006 to Non-Final Office Action date mailed May 30, 2006 for U.S. Appl. No. 10/320,211. |
Non-Final Office Action date mailed Mar. 7, 2007 for U.S. Appl. No. 10/320,211. |
Response filed Jun. 6, 2007 to Non-Final Office Action date mailed Mar. 7, 2007 for U.S. Appl. No. 10/320,211. |
Non-Final Office Action date mailed Aug. 27, 2007 for U.S. Appl. No. 10/320,211. |
Response filed Nov. 27, 2007 to Non-Final Office Action date mailed Aug. 27, 2007 for U.S. Appl. No. 10/320,211. |
Non-Final Office Action date mailed Feb. 25, 2008 for U.S. Appl. No. 10/320,211. |
Response filed May 14, 2008 to Non-Final Office Action date mailed Feb. 25, 2008 for U.S. Appl. No. 10/320,211. |
Notice of Allowance date mailed Jun. 11, 2008 for U.S. Appl. No. 10/320,211. |
Number | Date | Country | |
---|---|---|---|
20080275408 A1 | Nov 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10320211 | Dec 2002 | US |
Child | 12177588 | US | |
Parent | 09590333 | Jun 2000 | US |
Child | 10320211 | US |